BMS/Janssen Will Begin Phase III For Factor XIa Inhibitor Milvexian By Year-End

Phase II Showed Potential Beyond Prior Anticoagulants

Aug 28 2022

• By Mandy Jackson

Listen to this article

Bristol and Janssen reported Phase II data at the ESC Congress in secondary stroke prevention, an indication not covered by Factor Xa inhibitors. BMS unveiled a three-indication Phase III program.

stethoscope twisted in heart shape lying on cardiogram chart closeup — BMS unveiled three Phase III indications: secondary stroke prevention, acute coronary syndrome and atrial fibrillation • Source: Shutterstock

With data in hand from two Phase II clinical trials of milvexian, Bristol Myers Squibb Company and the Janssen Pharmaceutical Cos. of Johnson & Johnson now plan to kick off a Phase III program later this year to show definitively whether the Factor XIa inhibitor can be developed beyond the approved indications for the class’s predecessors – Factor Xa inhibitors, such as the BMS/Pfizer Inc. blockbuster anticoagulant Eliquis (apixaban).

Bristol and Janssen presented positive Phase II results on 28 August at the European Society of Cardiology (ESC) Congress in...

More from Cardiovascular

Aerovate Tanks On Trial Catastrophe
Mar 10 2025
• By Elizabeth Cairns
A disastrous Phase II miss for the pulmonary arterial hypertension candidate AV-101 leaves Aerovate drifting. Could Gossamer stand to benefit?
Cagrisema Leads The Charge For 2025
Mar 10 2025
• By Elizabeth Cairns
2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.
Evidence Growing For GLP-1s To Treat Alzheimer’s And Parkinson’s
Mar 10 2025
• By Andrew McConaghie
GLP-1 receptor agonists could play a big role in tackling neurodegeneration and a new academic study has raised expectations of Novo Nordisk’s latest semaglutide Phase III results
Kerendia Could Be Next Jewel In Bayer's Pharma Crown
Mar 10 2025
• By Kevin Grogan
CEO Bill Anderson would not be drawn on whether the drug, currently approved for chronic kidney disease associated with type 2 diabetes, will hit a previous forecast of €3bn peak sales, but expansion into heart failure may make that figure look conservative.

More from Therapeutic Category

Scrip Data Article Without An Author
Nov 19 2025
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]
Nov 12 2025
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC
Nov 12 2025
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.